What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Cardiogenic shock (n=5204). Intervention: Impella vs. IABP. Primary outcome: short-term mortality (RR 1.08, p=0.45).

What question did this study set out to answer?

To evaluate the clinical outcomes, short-term mortality, and adverse complication rates associated with the Impella mechanical circulatory support device in patients with cardiogenic shock.

March 25, 2022IJC Heart & VasculatureOpen Access

Use of Impella device in cardiogenic shock and its clinical outcomes: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Key result

In patients with cardiogenic shock, Impella use was associated with 47% short-term mortality and showed no significant difference compared to IABP (RR 1.08, p=0.45).

Why the study?

Cardiogenic shock is life-threatening and mechanical circulatory support may impact its clinical course, but the usefulness of the promising Impella device remains debated.

Does the Impella device improve short-term mortality compared to IABP in patients with cardiogenic shock?

Key Points

To evaluate the clinical outcomes, short-term mortality, and adverse complication rates associated with the Impella mechanical circulatory support device in patients with cardiogenic shock.
Systematic review and random-effects meta-analysis of 33 studies comprising N = 5,204 patients presenting with cardiogenic shock treated with Impella.
Assessed primary endpoint of short-term mortality alongside secondary endpoints of vascular access complications and major bleeding using meta-regression.
Overall short-term mortality was 47%, with younger age (p = 0.01), higher support level (p = 0.004), and pre-PCI insertion (p < 0.001) serving as significant moderators.
Vascular access complications occurred in 6.4% of patients (predicted by age, p = 0.05, and diabetes, p = 0.007), while major bleeding occurred in 16.4%.
Compared to intra-aortic balloon pumps, Impella demonstrated no significant difference in short-term mortality (RR = 1.08, p = 0.45) but had significantly higher rates of vascular access complications (p < 0.001) and major bleeding (p < 0.001).

Study Design

Type

Meta-Analysis (n=5,204)

Structured PICO

Does the Impella device improve short-term mortality compared to IABP in patients with cardiogenic shock?

Population

5,204 patients with cardiogenic shock treated with Impella across 33 retrospective studies.

Intervention

Impella device (percutaneous mechanical circulatory support)

Comparator

Intra-aortic balloon pump (IABP) in a subgroup analysis

Outcome

Short-term mortalityhard clinical

Main Result

Relative Risk: 1.08

p-value: p=0.45

In patients with cardiogenic shock, Impella use did not significantly improve short-term mortality compared to IABP but was associated with higher rates of major bleeding and vascular complications.

Limitations

Results derived from retrospective studies
Results derive from retrospective studies

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

No short-term mortality benefit of Impella vs IABP in CS; challenges routine escalation and leaves open need for RCTs.

Cite This Study

Panuccio et al. (2022) conducted a meta-analysis in Cardiogenic shock (n=5,204). Impella vs. IABP was evaluated on short-term mortality (RR 1.08, p=0.45). In patients with cardiogenic shock, Impella use was associated with 47% short-term mortality and showed no significant difference compared to IABP (RR 1.08, p=0.45).

synapsesocial.com/papers/6a660efde5f05bd63f7e2a2d https://doi.org/10.1016/j.ijcha.2022.101007

View Full Paper

Ask AI

Bookmark